











Canadian Association of Radiologists Prostate MRI White Paper

Canadian Association of Radiologists' Journal
2022, Vol. 0(0) 1–13
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/08465371221105532
journals.sagepub.com/home/caj


Silvia D. Chang, MD, FRCPC, FSAR, FCAR¹ ,
Caroline Reinhold, MD, MSc² ,
Iain D. C. Kirkpatrick, BSc (Gen.), BSc(Med.), MD, FRCP(C),
DABR, FSAR, FCAR, FACR³ ,
Sharon E. Clarke, MD, PhD, FRCPC⁴ , Nicola Schieda, MD⁵,
Casey Hurrell, PhD⁶ , Derek W. Cool, MD, PhD, FRCPC⁷ ,
Adam S. Tunis, MSc, MD, FRCPC⁸ ,
Abdullah Alabousi, MD, FRCPC⁹ ,
Brendan J. Diederichs, MD, FRCPC¹⁰, and
Masoom A. Haider, MD, FRCPC^{11,*} 

VERSION HISTORY
Published 2021
Reaffirmed June 2026

Abstract

Prostate cancer is the most common malignancy and the third most common cause of death in Canadian men. In light of evolving diagnostic pathways for prostate cancer and the increased use of MRI, which now includes its use in men prior to biopsy, the Canadian Association of Radiologists established a Prostate MRI Working Group to produce a white paper to provide recommendations on establishing and maintaining a Prostate MRI Programme in the context of the Canadian healthcare system. The recommendations, which are based on available scientific evidence and/or expert consensus, are intended to maintain quality in image acquisition, interpretation, reporting and targeted biopsy to ensure optimal patient care. The paper covers technique, reporting, quality assurance and targeted biopsy considerations and includes appendices detailing suggested reporting templates, quality assessment tools and sample image acquisition protocols relevant to the Canadian healthcare context.

Résumé

Le cancer de la prostate est la tumeur maligne la plus courante et la troisième cause de décès chez les hommes canadiens. À la lumière de l'évolution des voies diagnostiques du cancer de la prostate et l'utilisation accrue de l'IRM, qui inclut désormais son utilisation chez l'homme avant la biopsie, l'Association canadienne des radiologistes a créé un groupe de travail sur l'IRM de la prostate pour produire un livre blanc afin de fournir des recommandations sur l'établissement et le maintien d'un programme d'IRM de la prostate dans le contexte du système de santé canadien. Les recommandations, qui sont fondées sur les preuves

¹ Department of Radiology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada

² Augmented Intelligence & Precision Health Laboratory (AIPHL), Department of Radiology and the Research Institute of McGill University Health Centre, McGill University Health Centre, Montreal, QC, Canada

³ University of Manitoba, St Boniface General Hospital, Winnipeg, MB, Canada

⁴ Dalhousie University, Halifax, NS, Canada

⁵ Department of Diagnostic Imaging, The Ottawa Hospital- Civic Campus, Ottawa, ON, Canada

⁶ Canadian Association of Radiologists, Ottawa, ON, Canada

⁷ Department of Medical Imaging, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

⁸ Department of Medical Imaging, University of Toronto, North York General Hospital, Toronto, ON, Canada

⁹ Department of Radiology, McMaster University, St. Joseph's Healthcare, Hamilton, ON, Canada

¹⁰ Department of Radiology, University of Calgary, Calgary, AB, Canada

¹¹ Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

*Senior author

Corresponding Author:

Silvia D. Chang, Department of Radiology, University of British Columbia, Vancouver General Hospital, 899 West 12th Avenue, Vancouver, BC V5Z 1M9, Canada.
Email: silvia.chang@vch.ca

scientifiques disponibles et/ou sur un consensus d'experts, visent à maintenir qualité dans l'acquisition d'images, l'interprétation, le rapport et la biopsie ciblée pour assurer une prise en charge optimale des patients. Le papier couvre la technique, les rapports, l'assurance qualité et les considérations de biopsie ciblée et comprend des annexes détaillant les rapports suggérés des modèles, des outils d'évaluation de la qualité et des exemples de protocoles d'acquisition d'images pertinents pour le contexte des soins de santé au Canada.

Keywords

prostate cancer, prostate biopsy, magnetic resonance imaging, multiparametric MRI, quality improvement

Background and Rationale

The Canadian Association of Radiologists Prostate MRI Working Group is composed of abdominal and interventional radiologists in academic and community practice with expertise in prostate cancer imaging. Prostate cancer (PCa) is the most common malignancy and the third most common cause of death in Canadian men.¹ In the past decade, the utilization of prostate MRI has been steadily increasing and is anticipated to escalate further as it becomes part of the diagnostic pathway in detecting PCa in men prior to biopsy.²⁻⁷ The introduction of the Prostate Imaging and Data System (PI-RADS) in 2012 with subsequent updates and its current version 2.1 (PI-RADS v2.1) enables standardization in the technique, interpretation and reporting of prostate MRI.⁸⁻¹⁰ However, there remain variability and challenges to the practice of prostate MRI.¹¹⁻¹³ This white paper serves as a resource and provides recommendations on establishing and maintaining a Prostate MRI Programme in the context of the Canadian healthcare system. Quality in all the steps from image acquisition, interpretation, reporting and targeted biopsy is important to ensure optimal patient care. The recommendations from the panel are based on available scientific evidence and/or expert consensus (Table 1).

State of the Field in Canada

One in nine Canadian men will be diagnosed with PCa in their lifetime, and 11 Canadian men will die of it each day.¹ Multi-parametric sequences utilizing T2-weighted imaging, diffusion-weighted imaging (DWI) and dynamic contrast enhancement (DCE) have led to increased utilization of prostate MRI for detection, localization, staging, risk stratification, active surveillance, recurrence assessment, guidance for targeted-biopsy and focal therapies for PCa.¹⁴⁻²⁴ Prostate MRI has become the standard of practice in assessing patients at elevated risk with prior negative systematic biopsies in many practices.¹⁴

The diagnosis of prostate cancer traditionally has been made with systematic transrectal ultrasound (TRUS)-guided biopsy.^{25,26} However, this technique has its limitations with under detecting clinically significant cancer (csPCa) and over detecting clinically insignificant prostate cancer (ciPCa).²⁷⁻²⁹ The definition of csPCa is controversial but the most widely

adopted criterion is a pathological Gleason score $\geq 3+4$ also referred to as International Society of Urological Pathology Grade Group (ISUP GG) ≥ 2 .³⁰ Patients with ciPCa have indolent disease that is unlikely to result in mortality in their lifetime and thus these patients can be observed expectantly, known as active surveillance (AS).³¹

More recently, multiple randomized control and multicentre studies,³²⁻³⁶ including a Canadian randomized clinical trial,³⁶ have shown that prostate MRI detects more csPCa and detects less ciPCa compared to systematic biopsies with fewer biopsies required with MRI. This has resulted in many centres worldwide shifting the paradigm to utilizing prostate MRI in the diagnostic pathway before biopsy in men with risk of having csPCa.²⁻⁷ This change in practice is already in Ontario guidelines⁷ and is soon anticipated to expand to the rest of Canada. This surge in demand for prostate MRI will require accessibility to MRI scanners which is already limited and variable depending on location.^{37,38} For example, in Ontario, the percentage of cases performed within the targeted time range is 47%.³⁸

There is also variability in the acquisition and interpretation of prostate MRI despite the use of PI-RADS.¹¹⁻¹³ Thus, this expansion of prostate MRI should be executed with quality measures in place. These standards are currently lacking in Canada. This is especially prudent, given that suboptimal acquisition and interpretation can result in differing management decisions and treatment plans. Furthermore, MRI-targeted biopsy, wherein a suspicious lesion seen in MRI is subsequently targeted for biopsy, will also grow in demand as the number of prostate MRIs being performed continues to increase. Accessibility and training for MRI-targeted biopsy in addition to prostate MRI acquisition and interpretation should also be addressed.

Patient Pathway and Role of MRI in Prostate Cancer Diagnosis

The aim of multiparametric prostate MRI (mpMRI) early in the diagnostic pathway for PCa is to optimize patient outcomes through early and accurate detection of csPCa, reduction of unwarranted biopsies, reduction of detection of ciPCa and unnecessary intervention.^{9,10}

mpMRI in biopsy naïve patients has been shown in multicentre prospective randomized trials to decrease unnecessary biopsy and reduce over-detection of ciPCa in biopsy-naïve

Table 1. Consensus Recommendations for Performing and Interpreting Prostate in Canada.**Image Quality**

- 1 Image quality should be reported
- 2 10 consecutive representative cases should be reviewed every 6 months to ensure that they meet PI-RADS technical standards and that quality is deemed satisfactory

Interpretation and reporting

- 3 In addition to PI-RADS score, the PSA, age and indication for the exam should be recorded and included in all reports
- 4 To evaluate the radiologist's performance, institution-based audits or a mechanism for radiologists to receive feedback should be implemented
- 5 To evaluate the radiologists' interpretation performance, histopathologic feedback should be integrated, whenever possible. If no regular histopathological feedback is available, MDT rounds are encouraged
- 6 Radiologists should participate in MDT meetings or attend MDT-type workshops where patient-based clinical scenarios are discussed, if available locally or via remote access
- 7 Where possible based on local availability, MDT should include urology and radiology, with the optional addition of pathology, medical and radiation oncology as needed
- 8 The MDT should include MRI review with histology results from targeted biopsy and/or prostatectomy, where available

Training, credentialing and institutional feedback

- 9 Before interpreting prostate MRI, radiologists should receive training through either core theoretical prostate mpMRI courses and/or hands-on practice at workstations with supervised reporting
- 10 Radiologists should have read 50 cases with histological confirmation before beginning interpretation of prostate MRI.
- 11 Double reads should be considered by institutions with limited/preliminary expertise and/or low case volumes
- 12 Prostate radiologists should compare their performance with histopathological feedback
- 13 Prostate radiologists should have knowledge of the added value of MRI and the consequences of false-positive MRI.
- 14 Prostate radiologists should be aware of alternative diagnostic methods (risk stratification in diagnostic/treatment work-up)
- 15 Hands-on training and/or educational courses may be given by high throughput or highly experienced centres performing at least 500 cases per year

Methodological Note: To determine the consensus statements and recommendations above, the Canadian Association of Radiologists' Prostate MRI working group participated in a Delphi consensus process. The panel, which was comprised of 10 abdominal and interventional radiologists who are experts in prostate cancer imaging, completed two rounds of questionnaires to rate 22 statements across 3 categories: image quality, interpretation and reporting, training and credentialing. Questions were rated for agreement on a 7-point scale, with statements rated 6.0 to 7.0 by $\geq 60\%$ of panellists reaching consensus agreement in Round 1, and statements rated 1.0-2.9 by $\geq 60\%$ of panellists being removed due to consensual disagreement. Statements rated 3.0-5.9 were included in the second round of questionnaires, incorporating suggestions for rewording or rephrasing as indicated by anonymous comments from the working group. The same markers of agreement and disagreement were applied to the second round of the questionnaire. After the second round, the working group was convened to discuss the entire set of statements that had been rated 6.0 or higher and to ensure broad consensus on the possible practical and policy-related implications of the consensus statements.

patients compared to systematic biopsy.^{34,39,40} The Working Group supports the recommendations made by Cancer Care Ontario,⁷ as endorsed by the Canadian Urological Association,⁴¹ that for biopsy-naïve patients at elevated risk of csPCa, mpMRI be used prior to biopsy in patients who are candidates for curative management with suspected clinically localized prostate cancer.

Another common and more widely accepted indication for mpMRI is the evaluation of patients with a prior negative systematic biopsy and persistently elevated risk of csPCa. MRI provides an incremental improvement in the detection of csPCa in this population, particularly at the anterior fibromuscular stroma (AFMS) and apex.¹⁴

In addition to initial tumour detection, prostate MRI can be utilized to locally stage disease extent, which may be of use for both selections of optimal therapy, as well as surgical and radiation planning.^{42,43} The use of prostate MRI for local staging is debated as the sensitivity for detection of extraprostatic disease has been shown to be limited.

Multiparametric prostate MRI has been applied at many centres as a criterion for initial patient enrolment in active surveillance (AS) programmes and as a tool for the longitudinal monitoring need for repeat biopsy in AS. There is a growing body of literature that is improving our understanding of the most reliable imaging parameters to trigger repeat tissue sampling.^{31,44,45}

Finally, prostate MRI may be of use for the detection of local disease recurrence in treated patients with biochemical evidence of disease recurrence. MR imaging can be combined with clinical and biochemical parameters to allow for accurate and timely tumour detection.

Prostate MRI Technique

Although mpMRI acquisition protocols for prostate imaging serve as an important guide for end-users,¹⁰ site-, scanner- and patient-specific technical modifications may be required to achieve sufficient image quality. For example, adjustments to voxel volume and acquisition time for optimal signal-to-noise ratios will be required depending on whether prostate imaging is performed at 1.5 or 3T.⁴⁶ Sharing of best protocols and practices among radiologists and collaboration between physicists, technologists, vendor application specialists can ensure optimal image quality. For sample protocols for various manufacturers and magnet strengths, please see [Appendices A-D](#)

Hardware Considerations

Prostate mpMRI has been widely performed using both 1.5 T and 3T MRI scanners.⁴⁷ Although consistent diagnostic image quality can be achieved at 1.5 and 3T when optimized acquisition parameters are applied, the increased signal-to-noise ratio (SNR) afforded by 3T MRI scanners provides an important advantage that can be used to maximize spatial and/or temporal resolution. Disadvantages of 3T scanners include increased power deposition, signal heterogeneity and

susceptibility artifacts; however, these technical limitations are readily mitigated by contemporary state-of-the-art 3T MRI systems.⁴⁸ Therefore, this Working Group recommends that prostate imaging be performed at 3T whenever possible.⁴⁶ Specific indications for imaging at 1.5 T include the presence of implantable devices that are MR conditional at 1.5 T but not at 3T, and devices that may result in degraded image quality due to magnetic susceptibility artifact, for example, a metallic hip prosthesis. Performing prostate mpMRI at lower magnetic field strengths, that is, <1.5 T is not recommended given the current lack of clinical validation. Ultimately, when both 1.5 T and 3T are available, the consensus of the Working Group is that patients should be imaged in the 3T scanner unless contraindicated. If only 1.5 T is available careful attention must be paid to ensuring adequate image quality and gaining access to 3T systems is encouraged.

Recent advances in phased-array surface coil technology, pulse sequence and protocol optimization have reduced the gap in performance between studies acquired with and without an endorectal coil.⁵¹ This Working Group recommends that the use of integrated endorectal coils is not necessary, considering the significant workflow challenges associated with their use including cost, preparation time and patient acceptance. However, it may be advantageous for large patients where the SNR of the centrally located prostate gland may be suboptimal using only surface coils.

Patient Preparation

Currently, there is no consensus amongst prostate MRI experts regarding patient preparation with practices varying worldwide ([Table 2](#)). However, most experts agree that evacuation of the rectum prior to MRI is beneficial to minimize artifactual distortion of DWI due to the presence of air and/or stool in the rectum. Rectal enemas are an effective way to decrease rectal distension; however, the reported impact of enema on image quality has been inconsistent.^{10,49,50} The use of dietary modification has also been described as a method to reduce rectal gas.^{51,52}

The use of antiperistalsis agents such as hyoscine butylbromide has been shown to reduce motion-related artifacts and improve the depiction of anatomical detail of the prostate gland and adjacent structures on T2-weighted imaging.⁵³ However, the use of these agents increases the cost as well as the complexity of the MRI workflow. Furthermore, these agents have been associated with adverse events in patients with underlying cardiac conditions^{54,55}; therefore, the consensus of this Working Group is that antispasmodic agents are optional.^{10,46}

Imaging Acquisition Parameters

Standard prostate mpMRI acquisition protocols should include T2-weighted, T1-weighted, DWI and DCE sequences. The field of view (FOV) should be selected to optimize image

Table 2. Summary of described rectal preparation strategies for prostate MRI.

Technique	Mechanism	Results	Recommendation
Enema	Empties the rectum of stool, liquid and gas before MRI	Conflicting data, but, generally reduces the amount of rectal content and improves T2W and DWI image quality ^{51,52,103,104}	Is recommended approximately 3 hours prior to the MRI. This allows time for the enema to take effect and bowel irritation to resolve
Dietary modification	Low residue, clear fluids or no oral ingestion before MRI reduces the amount of gas in the rectum	Two studies demonstrating incremental benefit compared to enema alone, but inferior results to enema as a standalone method ^{51,52}	Clear fluids/NPO recommended beginning midnight before or a minimum of 6 hours before the time of MRI in cases of evening and night appointments. Low residue diets should begin 3–5 days prior to the MRI.
Anti-spasmodics	Decrease rectal peristalsis	Conflicting results, may improve T2W and to a lesser extent DWI image quality ^{52,81}	Dependent on facilities, resources, and staffing; may be considered as an adjunct to an enema, dietary modification
Catheter	Removes rectal gas	Two available studies, both show some benefit ^{49,104,105}	Not recommended; however, may be considered at time of MRI, if a large volume of rectal gas is identified and noted to be compromising image quality

quality while encompassing the entire prostate gland, adjacent periprostatic tissues and the seminal vesicles. In staging and post-treatment cases, the protocol should include a large FOV imaging through the entire pelvis to assess for lymphadenopathy and bone metastases.

The standard sequences of a mpMRI protocol should be acquired in the same imaging plane and at the same slice levels to facilitate lesion mapping across sequences. However, although using the maximum recommended slice thickness of 3 mm is feasible for T2-weighted sequences and DCE imaging, this may not be achievable with DWI, in particular at 1.5 T where SNR considerations may require an increase in slice thickness.^{10,46}

T2-weighted images should be acquired in the axial plane and both sagittal and coronal planes. Oblique axial imaging is not necessary and straight axial imaging is adequate. The coronal plane provides detailed anatomy of the apex, base as well as prostatic-seminal vesicle angle and is preferred over the sagittal plane. A sagittal plane using a rapid T2-weighted sequence can then be performed primarily for prostate volume assessments to save time. Both 2D and 3D T2 sequences provide comparable image quality and achieve similar accuracy for the detection of prostate cancer and extraprostatic extension.^{56–58} The choice of 3D vs 2D T2-weighted sequences remains at the discretion of each centre.

T1-weighted images are used primarily to determine the presence of haemorrhage. DWI should be acquired with at least two pre-determined b-values, a low b-value set at 50–100 s/mm² and an intermediate b-value set at 800–1000 s/mm² to optimize calculation of the apparent diffusion coefficient (ADC) maps and minimize diffusion kurtosis effects. In addition, a high b-value image of > 1400 s/mm² is required either as a separate acquisition or as an extrapolated image from the low and intermediate b-value acquisitions.^{10,59} Extrapolated images offer the advantage of decreased acquisition time, however, lesion conspicuity has been shown to be variable compared to directly acquired high b-value images.^{60,61}

DCE imaging should be performed using 3D T1-weighted gradient echo sequences to exploit the increased SNR afforded by 3D acquisitions techniques. The minimum temporal resolution of DCE acquisition is ≤15s given the qualitative nature of lesion enhancement assessment and lack of added diagnostic value from the higher temporal resolution.^{62,63}

Bi-Parametric MRI (bpMRI)

The use of bi-parametric MRI (bpMRI) refers to the removal of the DCE acquisition from the mpMRI protocol. Although a controversial topic, bpMRI is being considered as an alternative to mpMRI due to the significant savings that can be achieved in MRI time and cost of the contrast agent. This is highly relevant in the context of the expected increase in the volume of prostate MRI requests as it is adopted for biopsy-naïve patients. Although there are both single-centre studies and meta-analysis data showing noninferiority of bpMRI^{64–67} to mpMRI, concern

remains regarding the retrospective nature of these studies and the potential increase in indeterminate (PI-RADS 3) interpretations using only bpMRI. Prospective multicenter clinical trials or trials comparing the impact on decision making and outcomes between bpMRI and mpMRI are currently lacking. For this reason, mpMRI is still recommended as the standard of care by this Working Group; however, given anticipated resource pressures bpMRI can be performed at the discretion of the radiologist in centres that have demonstrated local bpMRI performance similar to mpMRI. For the population of patients who have undergone treatment, mpMRI with contrast should be used, as contrast is critical in assessing for recurrent disease

Reporting

Advances in speech recognition software in recent years have spurred an increased interest in structured radiology reports to improve consistency of reporting, report quality and a standardized lexicon that can easily be interpreted by other radiologists and non-radiology clinicians. A reporting template will ensure that no vital information needed by a clinician is left out of the report and is particularly helpful for those less experienced in interpreting prostate MRI in that it can serve as a guide to lead the radiologist through key findings required in a report. Structured reports facilitate audits for quality assurance purposes and research.^{68–71} A recent survey of the Society of Urologic Oncology showed that urologists overwhelmingly (90%) prefer either completely structured or hybrid structured reports (i.e. using a structured template with some free text fields for description) as well as PI-RADS standardized scoring of any lesions (86%).⁷²

Reporting of the nature and location of any lesion of concern in a standardized fashion is particularly critical for biopsy planning, as these procedures are often not performed by the radiologist who authored the original diagnostic report. Structured reporting has been shown to improve the accuracy of tumour localization and reduce the frequency of errors made during the performance of MRI-guided biopsies.⁷³ The standard localization of any lesions for biopsy on the PI-RADS v2 sector map and with series and image numbers included in the report aids localization in MR/ultrasound fusion biopsy, as do either illustrations, annotated images or 3D contouring.⁷⁴

The Working Group thus recommends either fully structured or hybrid structured reporting (see [Appendix E](#) Sample Reporting Template) using the PI-RADS v2.1 reporting system.¹⁰ Specifically, the PI-RADS V2.1 lexicon and sector map should be considered mandatory to facilitate the accuracy of communication between disciplines. Recommended components of the report include:

Clinical History/Indication: Include the provided clinical indication for the exam, patient age, date and PSA level

(if known), dates and results of any prior biopsies and any prior therapies.

Technique: Should state if the MR protocol is PI-RADS v2.1 compliant, field strength and coil used, and sufficient information on the pulse sequences used so that the recipient can determine if the study was biparametric or multiparametric. Reporting the b-value of the high b-value diffusion images is encouraged, along with a statement indicating image quality.

Comparison: Dates of prior studies used for comparison.

Findings: Prostate size should be reported L X W X H (AP and CC measured off midsagittal image and transverse measured off the corresponding axial image) with volume (indicate if calculated off ellipsoid formula or volumetric postprocessing) and PSA density (PSA divided by prostate volume). Utilizing PSA density is important, as patients with elevated PSA density are at an increased risk of malignancy. For example, in patients with PI-RADS 3 lesions, PSA density thresholds of approximately 0.1 to 0.15 have been suggested for biopsy. The presence of any haemorrhage should be reported as well as the degree of nodular hyperplasia, if present, along with any associated bladder changes.

Up to four individual lesions can be reported, in decreasing order of PI-RADS score/suspicion for malignancy. The location of the lesion should be indicated using the PI-RADS v2.1 sector map, and series and image numbers for multiple sequences should be given. The size of peripheral zone lesions should be taken from the ADC map, and transition zone lesions should be measured on the T2-weighted (T2W) images (other sequences where the lesion is best visualized may be used if these are inappropriate due to image quality concerns, and if used should be so indicated). Individual PI-RADS scores for T2W, diffusion-weighted imaging (DWI) and dynamic contrast enhancement (DCE) images should be given along with an overall score. Any evidence of involvement of the prostatic capsule/extraprostatic extension (indicate distance and location), seminal vesicles, bladder neck or neurovascular bundle should be reported or else a pertinent negative statement should be given indicating none of the above. If other incidental findings (e.g. cysts and prostatitis) are present, they can be reported at the end of this section.

Reports should indicate if there is any involvement of the visualized lymph nodes or bones, and if not there should be a pertinent negative statement given indicating no lymphadenopathy or bone lesions within the field of view of the exam. Other incidental findings (e.g. diverticular disease and hernias) can be reported last.

Impression: Any reported lesion of PI-RADS score 3 or greater should be summarized, along with any described disease outside of the prostatic capsule.

See [Appendix F](#) for PI-RADS v2.1 Assessment Tables.

Quality Assurance

Prostate mpMRI quality is important and should be both reported and monitored.⁷⁵ Image quality is affected by system-level and patient-level factors, both of which should be optimized. System-level factors include magnetic field strength,⁵³ pulse sequences performed and their parameters, use of endorectal coil,⁷⁶ age of equipment⁷⁷ and experience of the MR technologists and radiologists who perform and interpret the exams, respectively.^{78,79} Patient-level factors that may affect image quality include motion, metallic implants⁸⁰ and susceptibility artifact from gas in the rectum.⁸¹ Wide variation in mpMRI quality and compliance with recommendations on acquisition parameters has been observed^{77,82,83}; furthermore, what constitutes a poor vs a diagnostic quality examination remains generally undefined due to lack of standardized criteria.⁸⁴

The PI-QUAL system,⁸⁵ developed and applied using mpMRI data from the PRECISION trial,³⁴ is a proposed tool to assess the quality of prostate mpMRI consisting of both objective technical specifications (e.g. PI-RADS v2 technical specifications)⁹ and subjective criteria derived from the MR images using a 1–5 Likert scale (see [Appendix G](#): Suggested Image Quality Evaluation Form). The PI-QUAL schema is representative of the type of system needed for ensuring image quality across centres. Advantages of PI-QUAL are that it is straightforward to implement, has no cost and requires little training, making it potentially suitable for performing quality control audits. As the first available scoring system to assess prostate MRI quality, PI-QUAL will probably form the basis for future work and will undergo further refinements.⁸⁶ Notably, adherence to PI-RADS v2 minimum technical standards does not guarantee good image quality⁸⁷ and some standards may be too stringent.⁸³ Therefore, there is no single technical standard that can be universally applied, and the technical criteria may need to be modified to ensure diagnostic quality images for each institution and their own MR system. Future application of quantitative or automated assessment of image quality may be better than subjective systems like PI-QUAL, however, require development and validation.

Despite widespread acknowledgment regarding the importance of quality control in prostate mp-MRI, there are no published guidelines indicating the frequency and number of cases required for auditing purposes. Most experts on a recent European consensus panel voted for external and objective image quality assessment regularly at 6 months or longer intervals but there was no consensus on number of exams to be included.⁷⁵ Alternatively, image quality checks may be performed on a randomly selected sample of cases, in which case the majority of the panellists agreed that a selection of 5% of exams is most appropriate.⁷⁵

Audits can be performed by a designated radiologist, rota of mpMRI reporting radiologists or by an external audit. Cases should be randomly selected to represent all MRI machines used for prostate mp-MRI at a given centre and a cross-section

of performing MR technologists. Results of the audit should inform ongoing institutional quality control efforts with modification of technical parameters, patient preparation or MR technologist training, as appropriate.

Competency Benchmarking

Competency benchmarks for prostate MRI reporting are challenging to define. Studies establishing numerical thresholds are few and present conflicting results.⁸⁸ Moreover, investigators evaluating the importance of reader experience in prostate MRI have used differing endpoints including overall accuracy, inter-observer agreement and positive predictive value (PPV).⁸⁸⁻⁹² The Canadian Association of Radiologists (CAR) currently suggest that outcome data from mammography reporting should be reported including the date range of audit, total number of exams performed, number of BI-RADS 0, 4 and 5 cases and biopsy results of BI-RADS 4 and 5 lesions.⁹³ Furthermore, the CAR suggests radiologists supervise/interpret/report ≥ 150 breast MRI examinations over 36 months (e.g. ~ 50 exams per year).⁹³ A survey of radiologist members of the Society of Abdominal Radiology (SAR) revealed that among mainly abdominal subspecialist radiologists, over 80% of respondents report between 0 and 10 prostate MRIs per week.¹³ In a 2021 study, Davenport et al evaluated the performance of 18 subspecialty-trained radiologists who reported prostate MRI with PI-RADS version 2 over a ~ 4 -year time period. Radiologist years of experience ranged from 1 to 22 years and the median number of MRIs reported was 232 (~ 60 exams per year). The outcome evaluated was whole-gland PI-RADS v2 PPV dispersion among radiologists who interpreted ≥ 30 exams with pathological confirmation. The PPV results and dispersions were: PI-RADS 3 (22.1%; Inter-quartile range [IQR]: 10.0%–28.6%), PI-RADS 4 (49.2%; IQR: 41.4%–50.0%) and PI-RADS 5 (81.8%; IQR: 77.1–84.4%).⁹¹ It was the consensus of the Working Group that Radiologists should have read a minimum of 50 cases⁹² with histological confirmation before beginning interpretation of prostate MRI. (see [Table 2](#))

Targeted Biopsy Considerations

The emergence of mpMRI for the detection and localization of PCa has enabled targeted biopsy for prostate cancer diagnosis. Targeted biopsy involves directing biopsy cores at index lesions identified on mpMRI and this can be performed either in addition to or instead of conventional systemic TRUS biopsy sampling.

Targeted biopsy has shown benefit over systematic biopsy with higher rates of detection of significant PCa while reducing insignificant PCa detection.^{94,95} The three primary approaches for targeted biopsy are cognitive biopsy, MR-TRUS fusion biopsy (fusion biopsy) and MR in-bore biopsy (MR biopsy).

MR biopsy involves needle insertion within the MR suite using specialized hardware and software. This technique has

the benefit of directly visualizing the needle within the lesion on MRI to confirm adequate sampling; however, access is a challenge as most procedures require at least one hour of valuable MRI suite time.

Fusion biopsy systems align the MR lesions to TRUS using specialized software and/or hardware such that the mpMRI target for biopsy is displayed on the TRUS to allow for targeted biopsy under TRUS guidance. This approach benefits from providing a visible biopsy target outside of the MRI suite; however, the procedures require specialized equipment, are often longer than conventional systematic biopsy and inaccuracy in the MRI-TRUS fusion (including patient motion during the procedure) lead to inaccurate sampling. The optimal number of samples from target lesions remains the subject of investigation, but current data suggest that at least 3 samples should be obtained from index lesions.⁹⁶

Cognitive biopsy is the least expensive option as it uses a conventional TRUS probe to direct biopsies toward the perceived area of the suspicious mpMRI lesion. This technique requires no new hardware/software and does not substantially impact the current clinical workflow; however, it requires the operator to accurately correlate the MRI and TRUS orientations ('cognitive registration'), which risks inaccurate targeting.⁹⁷

Investigating which of the three targeted biopsy approaches is preferred continues without the optimal approach identified; however, some data and expert consensus suggest that fusion and/or MR biopsy might have superior diagnostic yield and be favoured over cognitive biopsy.⁹⁸⁻¹⁰¹

The route of biopsy is also of clinical importance. Historically, prostate biopsy was performed with a transrectal approach. This technique is familiar to many operators and offers simplicity and speed but has associated rates of urosepsis between .7 and 7% requiring antibiotic prophylaxis.¹⁰¹ Transperineal biopsy has lower urosepsis rates and may become the future standard. It is performed in lithotomy position and is the default for MR in bore biopsy but also used for fusion biopsy either with a brachytherapy grid as needle guide or freehand. Transperineal biopsy was traditionally performed under general anaesthesia, but recent studies have shown it can be performed under local anaesthesia as well.¹⁰²

Conclusion

The growing demand for prostate MRI has been occurring in the past decade with revised guidelines incorporating prostate MRI earlier in the cancer assessment pathway. There are multiple indications for prostate MRI which now includes men prior to biopsy. This will add to the existing demand for mpMRI. As MRI is challenging to access and an expensive, time-intensive resource, maintaining quality in all the steps from image acquisition, interpretation, reporting and targeted-biopsied is critical in optimizing

patient care. The Working Group encourages optimizing image quality and performing audits on a regular basis. Radiologists planning to interpret prostate MRI should undergo training and use a template for reporting. Obtaining feedback on interpretation of cases with pathology correlation should be performed as well as attending multidisciplinary rounds, if available (Table 1). The Working Group acknowledges the challenges for radiologists in low volume practices. To help maintain interpretation skills for those that have limited access to an adequate volume of cases, the Working Group intends to create a repository of cases that will be housed in the CAR Rad Academy platform for use by CAR members.

Acknowledgements

The working group would like to thank the radiologists from across Canada who participated in the survey which informed this work. The full results of the survey are available in the **Supplementary Material** for this article. The Working Group would also like to acknowledge the CAR members who provided their peer review and feedback on draft versions of this white paper.










Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no specific financial support for the research, authorship, and/or publication of this article. Dr. Haider receives support for related work from the Ontario Institute of Cancer Research (OICR).

ORCID iDs

Silvia D. Chang  <https://orcid.org/0000-0002-9201-8114>
 Caroline Reinhold  <https://orcid.org/0000-0002-8852-3273>
 Iain D. C. Kirkpatrick  <https://orcid.org/0000-0001-8951-5016>
 Sharon E. Clarke  <https://orcid.org/0000-0001-5759-5808>
 Casey Hurrell, PhD  <https://orcid.org/0000-0003-0453-2576>
 Derek W. Cool  <https://orcid.org/0000-0003-1095-3553>
 Adam S. Tunis  <https://orcid.org/0000-0002-8551-9885>
 Abdullah Alabousi  <https://orcid.org/0000-0001-8481-5087>
 Masoom A. Haider  <https://orcid.org/0000-0002-7165-8315>

Supplemental Material

Supplemental material for this article is available online.

References

1. *Prostate Cancer Statistics - Canadian Cancer Society*. www.cancer.ca, <https://www.cancer.ca:443/en/cancer-information/cancer-type/prostate/statistics/?region=on> (accessed 17 August 2021).

2. Padhani AR, Barentsz J, Villeirs G, et al. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. *Radiology*. 2019;292:464-474.
3. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. *Eur Urol*. 2017;71:630-642.
4. NICE Guidance - Prostate cancer: diagnosis and management: © NICE (2019) Prostate cancer: diagnosis and management. *BJU Int* 2019; 124: 9–26.
5. Bjurlin MA, Carroll PR, Eggner S, et al. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. *J Urol*. 2020;203:706-712.
6. Agency for Care Effectiveness. *MRI-US Fusion Targeted Biopsy for Diagnosis of Prostate Cancer: Technology Guidance from the MOH Medical Technical Advisory Committee*. Singapore Ministry of Health. accessed 17 August 2021 [https://www.ace-hta.gov.sg/docs/default-source/med-tech/mri-us-fusion-targeted-biopsy-for-diagnosis-of-prostate-cancer-\(as-of-30-apr-2021\).pdf](https://www.ace-hta.gov.sg/docs/default-source/med-tech/mri-us-fusion-targeted-biopsy-for-diagnosis-of-prostate-cancer-(as-of-30-apr-2021).pdf) 30 April 2021.
7. Haider M, Brown J, Chin J, et al. Multiparametric Magnetic Resonance Imaging In the Diagnosis Of Clinically Significant Prostate Cancer. 27–2 Version 2. Toronto, ON: Ontario Health (Cancer Care Ontario). accessed 17 August 2021 <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/281> 11 February 2021.
8. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. *Eur Radiol*. 2012;22:746-757.
9. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol*. 2016;69:16-40.
10. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. *Eur Urol*. 2019;76:340-351.
11. Rosenkrantz AB, Oto A, Turkbey B, Westphalen AC. Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look. *Am J Roentgenol*. 2016;206: 1179-1183.
12. Greer MD, Brown AM, Shih JH, et al. Accuracy and agreement of PIRADSV2 for prostate cancer mpMRI: A multireader study. *J Magn Reson Imag*. 2017;45:579-585.
13. Chang SD, Margolis DJA, Turkbey B, Arnold AA, Verma S. Practice Patterns and Challenges of Performing and Interpreting Prostate MRI: A Survey by the Society of Abdominal Radiology Prostate Disease-Focused Panel. *Am J Roentgenol*. 2021;216: 952-959.
14. Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. *J Urol*. 2016;196: 1613-1618.
15. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic

- contrast-enhanced MRI for prostate cancer diagnosis- Correlation with biopsy and histopathology. *J Magn Reson Imag.* 2006;24:108-113.
16. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. *Am J Roentgenol.* 2007;189:323-328.
 17. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. *J Magn Reson Imag.* 2007;25:146-152.
 18. Kitajima K, Kaji Y, Fukabori Y, Yoshida K-I, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. *J Magn Reson Imag.* 2010;31:625-631.
 19. Kozlowski P, Chang SD, Meng R, et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T - quantitative correlation with biopsy. *Magn Reson Imag.* 2010;28:621-628.
 20. Franiel T, Stephan C, Erbersdobler A, et al. Areas Suspicious for Prostate Cancer: MR-guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding- Multiparametric MR Imaging for Detection and Biopsy Planning. *Radiology.* 2011;259:162-172.
 21. Hambroek T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. *J Urol.* 2010;183:520-528.
 22. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. *Int J Radiat Oncol Biol Phys.* 2008;70:425-430.
 23. Panebianco V, Villeirs G, Weinreb JC, et al. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. *Eur Urol Oncol.* 2021;S2588-9311(21):00027-00034.
 24. Elkhoury FF, Simopoulos DN, Marks LS. MR-guided biopsy and focal therapy. *Curr Opin Urol.* 2018;28:93-101.
 25. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *J Urol.* 1989;142:71-74.
 26. Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. *World J Urol.* 2007;25:11-17.
 27. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. *J Urol.* 2001;166:104-110.
 28. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. *Eur Urol.* 2010;58:831-835.
 29. Carlsson S, Jäderling F, Wallerstedt A, et al. Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial. *BJU Int.* 2016;118:205-212.
 30. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol.* 2016;40:244-252.
 31. Giganti F, Kirkham A, Allen C, et al. Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations. *Am J Roentgenol.* 2021;216:943-951.
 32. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *JAMA.* 2015;313:390-397.
 33. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet.* 2017;389:815-822.
 34. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med.* 2018;378:1767-1777.
 35. Drost F-JH, Osses D, Nieboer D, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. *Eur Urol.* 2020;77:78-94.
 36. Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. *JAMA Oncol.* 2021;7:534-542.
 37. Sutherland G, Gibbard R, Russell N, et al. *The Value of Radiology, Part II.* Ottawa, ON: The Conference Board of Canada; 2019. accessed 14 September 2020 <https://www.conferenceboard.ca/e-library/abstract.aspx?did=10328>.
 38. *MRI and CT Scan Wait Times Diagnostic Imaging – Health Quality Ontario (HQO)*, <https://www.hqontario.ca/System-Performance/Wait-Times-for-Diagnostic-Imaging> (accessed 17 August 2021).
 39. Porpiglia F, Manfredi M, Mele F, et al. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. *Eur Urol.* 2017;72:282-288.
 40. Tonttila PP, Lantto J, Pääkkö E, et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. *Eur Urol.* 2016;69:419-425.
 41. Mason RJ, Marzouk K, Finelli A, et al. UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021

- Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. *Canadian Urological Association Journal*. 2022;16:E184-E196.
42. Valentin B, Schimmöller L, Ullrich T, et al. Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer. *Abdominal Radiology*. 2021;46:2751-2759.
 43. de Rooij M, Hamoen EHJ, Witjes JA, Barentsz JO, Rovers MM. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. *Eur Urol*. 2016;70:233-245.
 44. Schiavina R, Droghetti M, Novara G, et al. The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. *Urol Oncol Semin Orig Investig*. 2021;39:433.e1-433.e7.
 45. Stavrinides V, Giganti F, Trock B, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. *Eur Urol*. 2020;78:443-451.
 46. Purysko AS, Baroni RH, Giganti F, et al. PI-RADS Version 2.1: A Critical Review, From the AJR Special Series on Radiology Reporting and Data Systems. *Am J Roentgenol*. 2021;216:20-32.
 47. Leake JL, Hardman R, Ojili V, et al. Prostate MRI: access to and current practice of prostate MRI in the United States. *J Am Coll Radiol*. 2014;11:156-160.
 48. Mazaheri Y, Vargas HA, Nyman G, Akin O, Hricak H. Image Artifacts on Prostate Diffusion-weighted Magnetic Resonance Imaging. *Acad Radiol*. 2013;20:1041-1047.
 49. Lim C, Quon J, McInnes M, Shabana WM, El-Khodary M, Schieda N. Does a cleansing enema improve image quality of 3T surface coil multiparametric prostate MRI? *J Magn Reson Imag : JMRI*. 2015;42:689-697.
 50. Coskun M, Mehralivand S, Shih JH, et al. Impact of bowel preparation with Fleet's™ enema on prostate MRI quality. *Abdominal radiology (New York)*. 2020;45:4252-4259.
 51. Purysko AS, Mielke N, Bullen J, et al. Influence of Enema and Dietary Restrictions on Prostate MR Image Quality: A Multi-reader Study. *Acad Radiol*. 2022;29:4-14.
 52. Sathiadoss P, Haroon M, Osman H, et al. Comparison of 5 Rectal Preparation Strategies for Prostate MRI and Impact on Image Quality. *Can Assoc Radiol J*. 2021;73:346-354.
 53. Ullrich T, Quentin M, Oelers C, et al. Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: A prospective comparison study of image quality. *Eur J Radiol*. 2017;90:192-197.
 54. Dyde R, Chapman AH, Gale R, Mackintosh A, Tolan DJM. Precautions to be taken by radiologists and radiographers when prescribing hyoscine-N-butylbromide. *Clin Radiol*. 2008;63:739-743.
 55. *Hyoscine Butylbromide (Buscopan) Injection: Risk of Serious Adverse Effects in Patients with Underlying Cardiac Disease*. GOV.UK, <https://www.gov.uk/drug-safety-update/hyoscine-butylbromide-buscopan-injection-risk-of-serious-adverse-effects-in-patients-with-underlying-cardiac-disease> (accessed 21 December 2021).
 56. Rosenkrantz AB, Neil J, Kong X, et al. Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. *Am J Roentgenol*. 2010;194:446-452.
 57. Tanaka U, Ueno Y, Morinaga Y, et al. Value of three-dimensional T2-weighted turbo spin-echo imaging with tissue-specific variable refocusing flip angle for 3-T magnetic resonance imaging of prostate cancer: comparison with conventional two- and three-dimensional T2-weighted turbo spin-echo imaging. *Jpn J Radiol*. 2017;35:707-717.
 58. Westphalen AC, Noworolski SM, Harisinghani M, et al. High-Resolution 3-T Endorectal Prostate MRI: A Multireader Study of Radiologist Preference and Perceived Interpretive Quality of 2D and 3D T2-Weighted Fast Spin-Echo MR Images. *Am J Roentgenol*. 2016;206:86-91.
 59. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Head-To-Head Comparison Between High- and Standard-b-Value DWI for Detecting Prostate Cancer: A Systematic Review and Meta-Analysis. *Am J Roentgenol*. 2018;210:91-100.
 60. Jendoubi S, Wagner M, Montagne S, et al. MRI for prostate cancer: can computed high b-value DWI replace native acquisitions? *Eur Radiol*. 2019;29:5197-5204.
 61. Grant KB, Agarwal HK, Shih JH, et al. Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer. *Abdom Imag*. 2015;40:578-586.
 62. Ream JM, Doshi AM, Dunst D, et al. Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer. *J Magn Reson Imag*. 2017;45:1464-1475.
 63. Othman AE, Falkner F, Weiss J, et al. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate. *Invest Radiol*. 2016;51:290-296.
 64. Alabousi M, Salameh J-P, Gusenbauer K, et al. Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-naïve patients: a diagnostic test accuracy systematic review and meta-analysis. *BJU Int*. 2019;124:209-220.
 65. Kang Z, Min X, Weinreb J, Li Q, Feng Z, Wang L. Abbreviated Biparametric Versus Standard Multiparametric MRI for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. *Am J Roentgenol*. 2019;212:357-365.
 66. Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. *Radiology*. 2017;285:493-505.
 67. Bosaily AE-S, Frangou E, Ahmed HU, et al. Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. *Eur Urol*. 2020;78:503-511.

68. Magnetta MJ, Donovan AL, Jacobs BL, Davies BJ, Furlan A. Evidence-Based Reporting: A Method to Optimize Prostate MRI Communications With Referring Physicians. *Am J Roentgenol*. 2018;210:108-112.
69. Schwartz LH, Panicek DM, Berk AR, Li Y, Hricak H. Improving Communication of Diagnostic Radiology Findings through Structured Reporting. *Radiology*. 2011; 260:174-181.
70. Ganeshan D, Duong P-AT, Probyn L, et al. Structured Reporting in Radiology. *Acad Radiol*. 2018;25:66-73.
71. Wetterauer C, Winkel DJ, Federer-Gsponer JR, et al. Structured reporting of prostate magnetic resonance imaging has the potential to improve interdisciplinary communication. *PLoS One*. 2019;14:e0212444.
72. Spilseth B, Ghai S, Patel NU, Taneja SS, Margolis DJ, Rosenkrantz AB. A Comparison of Radiologists' and Urologists' Opinions Regarding Prostate MRI Reporting: Results From a Survey of Specialty Societies. *Am J Roentgenol*. 2018; 210:101-107.
73. Wetterauer C, Winkel DJ, Federer-Gsponer JR, et al. Novices in MRI-targeted prostate biopsy benefit from structured reporting of MRI findings. *World J Urol*. 2020; 38:1729-1734.
74. Westhoff N, Siegel F, Peter C, et al. Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection. *World J Urol*. 2019;37:327-335.
75. de Rooij M, Israël B, Tummers M, et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. *Eur Radiol*. 2020;30:5404-5416.
76. Gawlitza J, Reiss-Zimmermann M, Thörmer G, et al. Impact of the use of an endorectal coil for 3 T prostate MRI on image quality and cancer detection rate. *Sci Rep*. 2017;7:40640.
77. Burn PR, Freeman SJ, Andreou A, Burns-Cox N, Persad R, Barrett T. A multicentre assessment of prostate MRI quality and compliance with UK and international standards. *Clin Radiol*. 2019;74:894e19.
78. Engels RRM, Israël B, Padhani AR, Barentsz JO. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. *Eur Urol*. 2020;77:457-468.
79. Stabile A, Giganti F, Kasivisvanathan V, et al. Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. *European Urology Oncology*. 2020;3:145-167.
80. Czarniecki M, Caglic I, Grist JT, et al. Role of PROPELLER-DWI of the prostate in reducing distortion and artefact from total hip replacement metalwork. *Eur J Radiol*. 2018;102: 213-219.
81. Brennan DL, Lazarakis S, Lee A, Tan TH, Chin KY, Oon SF. Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An 'Evidence-Based Practice' review of the literature. *Abdominal Radiology*. 2021;46:2770-2778.
82. Coşkun M, Sarp AF, Karasu Ş, et al. Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS v2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey. *Diagn Interv Radiol Ank Turk*. 2019;25:421-427.
83. Esses SJ, Taneja SS, Rosenkrantz AB. Imaging Facilities' Adherence to PI-RADS v2 Minimum Technical Standards for the Performance of Prostate MRI. *Acad Radiol*. 2018;25: 188-195.
84. Giganti F, Kasivisvanathan V, Kirkham A, et al. Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. *Br J Radiol*. 2022;95:20210415.
85. Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. *European Urology Oncology*. 2020;3:615-619.
86. Giganti F, Kirkham A, Kasivisvanathan V, et al. Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. *Insights into Imaging*. 2021;12:59.
87. Sackett J, Shih JH, Reese SE, et al. Quality of Prostate MRI: Is the PI-RADS Standard Sufficient? *Acad Radiol*. 2021;28: 199-207.
88. Gatti M, Faletti R, Calleri G, et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). *Abdominal Radiology*. 2019; 44:1883-1893.
89. Kang HC, Jo N, Bamashmos AS, et al. Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters. *European Urology Open Science*. 2021;27:53-60.
90. Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. *Radiology*. 2020;296:76-84.
91. Davenport MS, Downs E, George AK, et al. Prostate Imaging and Data Reporting System Version 2 as a Radiology Performance Metric: An Analysis of 18 Abdominal Radiologists. *J Am Coll Radiol JACR*. 2021;S1546-1440(21): 00234-00239.
92. Salka BR, Shankar PR, Troost JP, Khalatbari S, Davenport MS. Effect of Prostate MRI Interpretation Experience on PPV Using PI-RADS Version 2: A 6-Year Assessment Among Eight Fellowship-Trained Radiologists. *Am J Roentgenol*. 2022. Epub ahead of print. doi:10.2214/AJR.22.27421.
93. Appavoo S, Aldis A, Causer P, et al. *CAR Practice Guidelines and Technical Standards for Breast Imaging and Intervention*. Ottawa, ON: Canadian Association of Radiologists. accessed 23 July 2021 https://car.ca/wp-content/uploads/car_breastimagingguidelines_2016_en.pdf. 17 September 2016.
94. Kasivisvanathan V, Stabile A, Neves JB, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*. 2019;76:284-303.

95. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med*. 2018;378:1767-1777.
96. Zhang M, Milot L, Khalvati F, et al. Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. *Radiology*. 2019;291:83-89.
97. Cool DW, Zhang X, Romagnoli C, Izawa JI, Romano WM, Fenster A. Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. *Am J Roentgenol*. 2015;204:83-91.
98. Watts KL, Frechette L, Muller B, et al. Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. *Urol Oncol*. 2020;38:734.
99. Prince M, Foster BR, Kaempf A, et al. In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting. *Am J Roentgenol*. 2021;217:1123-1130. Epub ahead of print 1 March 2021. doi:[10.2214/AJR.20.25207](https://doi.org/10.2214/AJR.20.25207).
100. Costa DN, Cai Q, Xi Y, et al. Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies. *Radiology: Imaging Cancer*. 2021;3:e200123.
101. Chang SD, Ghai S, Kim CK, et al. MRI-Targeted Prostate Biopsy Techniques: AJR Expert Panel Narrative Review. *Am J Roentgenol*. 2021;21:26154. AJR.
102. Stefanova V, Buckley R, Flax S, et al. Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability. *J Urol*. 2019;201:1121-1126.
103. Plodeck V, Radosa CG, Hübner H-M, et al. Rectal gas-induced susceptibility artefacts on prostate diffusion-weighted MRI with epi read-out at 3.0 T: does a preparatory micro-enema improve image quality? *Abdominal Radiology*. 2020;45:4244-4251.
104. Reischauer C, Cancelli T, Malekzadeh S, Froehlich JM, Thoeny HC. How to improve image quality of DWI of the prostate-enema or catheter preparation? *Eur Radiol*. 2021;31:6708-6716.
105. Huang Y-H, Özütemiz C, Rubin N, Schat R, Metzger GJ, Spilseth B. Impact of 18-French Rectal Tube Placement on Image Quality of Multiparametric Prostate MRI. *Am J Roentgenol*. 2021;217:919-920.

0.Appendix A: Prostate MRI Protocol for Siemens Aera 1.5T

Sequence	FOV (pFOV)	Thickness(Gap)	Resolution	Phase	TR	TE	Comments
Axial T2w FSE	< 240 mm	3 mm (0 mm)	320(p)x320(f)	R > L	3000-6000 ms	>80 ms	High-resolution images covering seminal vesicles and entire prostate
Coronal T2w FSE	< 240 mm	3 mm (0 mm)	320(p)x320(f)	S > I	3000-6000 ms	>80 ms	High-resolution images covering seminal vesicles and entire prostate
Sagittal T2w FSE*	< 240 mm	3 mm (0 mm)	320(p)x320(f)	A > P	3000-6000 ms	>80 ms	High-resolution images covering seminal vesicles and entire prostate. *Option to use rapid T2w sequence to save time
Sagittal T2w SPACE	200 mm	0.8 mm (0 mm)	256 x 256	A > P	1100 ms	133 ms	High-resolution volumetric images useful for fusion biopsies
Axial DWI	< 320 mm	3 mm (0 mm)	128(p)x128(f)	A > P	5300 ms	64 ms	Three B-values = 0-100, 800-1000, >=1400
Axial VIBE	<240 mm	3 mm	144(p)x144(f)	A > P	<100 ms	<5 ms	
Axial VIBE dynamic	<240 mm	3 mm	144(p)x144(f)	A > P	<100 ms	<5 ms	Required: Subtractions Phases: Temporal resolution ≤ 15 seconds per phase. Continuous image data acquisition with a total observation time of >=2 min
Axial T1w Pelvis	320-360 mm	5 mm (1 mm)	5.0 mm (1.0 mm)	R>L	<700 ms	min	Cover entire bony pelvis

Preferred viewing window and level for ADC is 1400x1400

Prostate Multiparametric Protocol

Coil: Multi-channel body or pelvis coil **Position:** Supine, arms down **Orientation:** Feet first

Scan Coverage: Include prostate gland and seminal vesicles

Gadolinium contrast dose: 0.1mL/kg by body weight.

Power injector rate: 2-3mL/sec flow rate with minimum of 20-30mL saline chaser

Appendix B: Prostate MRI Protocol for Siemens 3T

Scanner: 3.0 T Skyra Siemens

Software version: VE11E

Positioning: Supine head first, arms down

Coil: 2 phased array coils (cover abdomen and pelvis)

Contrast: Gadovist IV, weight-based

Injection Rate: 3.0 ml/s

Coverage:

- Sag: Include entire prostate and seminal vesicles.
- Cor oblique: Angle parallel to anterior rectal wall at the level of the prostate. Include entire prostate and seminal vesicles.
- Ax oblique: Angle perpendicular to anterior rectal wall at the level of the prostate (orthogonal to the Cor oblique). Include entire prostate and lower half of seminal vesicles.
- Ax abdomen: Cover entire abdomen from liver dome to aortic bifurcation.
- Ax pelvis: Cover from aortic bifurcation to perineum.

Protocol parameters on following page.

Routine Prostate							
	Sag Haste	Cor Obl T2 TSE	Ax Obl T2 TSE	Ax Obl EPI DWI	Ax Obl Resolve (b2000)	Ax Obl DCE (3D VIBE)	Ax T1 2 Stations Abdomen & Pelvis (3D VIBE FS)
TR / TE (ms)	1400 / 92	4000 / 101	4000 / 100	6100 / 81	4560 / 67	3.82 / 1.22	3.22 / 1.21
ETL / es (ms)	-- / 4.02	25 / 11.2	15 / 10.1	96 / 0.9	67 / 0.3	--	--
Flip Angle (deg)	160	160	160	180	180	15	9
Field of View (mm)	256 x 256	180 x 180	180 x 180	200 x 200	220 x 180	200 x 200	380 x 285
Acquired Matrix	256 x 256	320 x 224	320 x 288	130 x 96	90 x 81	160 x 96	320 x 180
Slices / Gap	22 / 0	19 / 20%	30 / 0	30 / 0	20 / 0	30	72
Resolution (mm)	1.0 x 1.0 x 5.0	0.6 x 0.8 x 3.0	0.62 x 0.69 x 3.0	1.5 x 2.1 x 3.0	2.4 x 2.20 x 4.0	1.3 x 1.8 x 3.0	1.2 x 1.6 x 3.0
Parallel	3	2	2	2	2	2	2x2 Caipirinha
Averages	1	2	3	6,14	8	1	1
Bandwidth (Hz/px)	700	200	200	1282	1208	520	445
PE-direction	AP	RL	RL	RL	AP	RL	AP
Options	50% OS	100% OS	100% OS	50% OS PPF 7/8 b0,1000 SAT (L,R) SPAIR	50% OS SAT (A,S) SPAIR b2000	100% OS 46.7% Slice OS 50% Slice res. PPF 7/8 SPF 6/8 25 phases (0:09 temp. res)	22.2% Slice OS 55% Slice res.
Time	0:31	2:34	3:46	6:38	7:31	3:48	0:10 x 2

PPF: Phase partial Fourier, SPF: Slice partial Fourier, OS: Oversampling, FS: Fat saturation; SAT: Spatial Saturation, Obl: Oblique

Appendix C: Prostate MRI Protocol for Philips 3T

Prostate Multiparametric Protocol

Coil: Muli-channel body or pelvis coil **Position:** Supine, arms down **Orientation:** Feet first

Scan Coverage: Include prostate gland and seminal vesicles

Sequence	FOV (pFOV)	Thickness (Gap)	Resolution	Phase	TR	TE	Comments
Axial T2w FSE	180 mm	3 mm (0 mm)	300 x 328	A > P	3000-6000 ms	100	High resolution images covering seminal vesicles and prostate
Coronal T2w FSE	180 mm	3 mm (0 mm)	300 x 262	R > L	3000-6000 ms	100	High resolution images covering seminal vesicles and prostate
Sagittal T2w FSE*	180 mm	3 mm (0 mm)	360 x 292	A > P	3000-6000 ms	90	High resolution images covering seminal vesicles and prostate *Optional - rapid T2W sequences to save time
Axial DWI**	300 mm	3 mm (0 mm)	120 x 120	A > P	6100 ms	89	Acquired B-Values: 0, 400, 800, 1400 **Option to extrapolate a higher B-Value (2000)
Axial T1 (3D THRIVE) Full Pelvis	340 mm	4.4 mm (2.2 mm)	244 x 244	A > P	4.1 ms	2.3	Covers entire bony pelvis
Axial THRIVE Dynamic	180 mm	6 mm (3 mm)	120 x 117	A > P	4.3 ms	2.3	Phases = 30, Temporal Resolution = 8.9 seconds per phase, continuous image data acquisition, total time = 4:28. Required: Subtractions
Axial T1 FS (3D THRIVE) Post-Gad	340 mm	4.4 mm (2.2 mm)	244 x 244	A > P	4.1 ms	2.3	Delayed post-gad images Covers entire bony pelvis

Gadolinium contrast dose: 0.1mL/kg by body weight.

Power injector rate: 2-3mL/sec flow rate with minimum of 20-30mL saline chaser

Appendix D: Prostate MRI Protocol for GE 3T Discovery

Prostate Multiparametric Protocol

Coil: 32 channel cardiac array coil by Invivo

Position: Supine, arms down

Orientation: Feet first

Scan Coverage: Include prostate gland and seminal vesicles

Sequence	FOV (pFOV)	Thickness (Gap)	Resolution	Phase	TR	TE	Comments
Axial T2w FSE	200 mm	3 mm (0 mm)	500 x 300	R > L	3000-6000 ms	110ms	ETL = 23, NEX = 5, NPW, EDR, TRF, ARC, anterior saturation band
Coronal T2w FSE	200 mm	3 mm (0 mm)	320x 320	R > L	3000-6000 ms	100 ms	ETL =25, NEX = 6, NPW, ZIP512, EDR, TRF, ARC
Sagittal T2w FSE	240 mm	3 mm (0.5 mm)	320 x 288	A > P	3000-6000 ms	120 ms	ETL = 21, NEX = 4, NPW, EDR, TRF, ZIP 512, ARC
Axial DWI (FOCUS)	240 mm (phase FOV= 0.5)	4 mm (0 mm)	160 x 96	A > P	4500 ms	63 ms	Acquired B-Values: 50, 1400 sec/mm ² NEX = 2 for b = 50; NEX = 16 for b = 1400 **Option to extrapolate a higher b-Value
Axial T1 (3D LAVA FLEX) Full Pelvis	300 mm	4.0 mm (interpolated to 2.0 mm)	256 x 256	R > L	3.8 ms	1.7 ms	Covers entire bony pelvis NPW, EDR, ZIP512, ZIP2, ARC
Axial DISCO Dynamic	340 mm	3 mm	224 x 192	A > P	3.8 ms	1.7 ms	Centered on prostate, Slices per location = 60, Phases = 59, Temporal Resolution = 3-4 seconds per phase, continuous image data acquisition; injection rate 2 ml/s
Axial T1 FS (3D LAVA FLEX) Post-Gad	300 mm	4.0 mm (2.0 mm)	256 x 256	R > L	3.8 ms	1.7 ms	Delayed post-gad images Covers entire bony pelvis NPW, EDR, ZIP512, ZIP2, ARC

ETL – echo train length; NEX – number of acquisitions, NPW – no phase wrap; EDR – extended dynamic range; TRF – tailored RF; ARC - Autocalibrating Reconstruction for Cartesian imaging

Appendix E-: Sample Reporting Template (Hybrid Structured Report)

Clinical History: [] PSA: []. Prior biopsies: []. Prior therapies: [].

Technique: Field strength: []. Coil: []. Pulse sequences: []. Image quality: [].

Comparison: [].

Findings:

Prostate size: Dimensions [] for a volume of []. PSA density [].

Hemorrhage: [].

Peripheral Zone: [].

Transition Zone: [].

Central zone and Anterior Fibromuscular Stroma: []

Lesion [insert # of lesion; may repeat this lesion subtemplate as necessary up to 4 lesions].

Location: []. Series/image numbers: [].

Size: [].

T2W score: [].

DWI score: [].

DCE score: [].

Overall score: [].

Status of prostatic capsule / neurovascular bundles / seminal vesicles / bladder neck: [].

Status of lymph nodes: [].

Status of visualized bones: [].

Other extraprostatic findings: [].

Impression: [].

Note: [] = Free text. Categories that remain constant between exams (e.g. field strength, coil used, pulse sequences) can become a permanent part of the template in lieu of free text.

Appendix F: PI-RADS v2.1 Assessment Tables

PI-RADS Assessment for T2W

Score	Peripheral Zone
1	Uniform hyperintense signal intensity (normal)
2	Linear or wedge-shaped hypointensity or diffuse mild hypointensity, usually indistinct margins
3	Heterogeneous signal intensity or non-circumscribed, rounded, moderate hypointensity Includes others that do not qualify as 2, 4 or 5
4	Circumscribed, homogeneous moderate hypointense focus/mass confined to prostate and <1.5 cm in greatest dimension
5	Same as 4 but ≥ 1.5 cm in greatest dimension or definite extraprostatic extension/invasive behavior
Score	Transition Zone
1	Normal appearing TZ (rare) or a round, completely encapsulated nodule ('typical nodule')
2	A mostly encapsulated nodule or a homogeneous circumscribed nodule without encapsulation ('atypical nodule') or a homogeneous mildly hypointense area between nodules
3	Heterogeneous signal intensity with obscured margins, including others that do not quality as 2, 4, or 5
4	Lenticular or noncircumscribed, homogeneous, moderately hypointense, and <1.5 cm in the greatest dimension
5	Same as 4, but ≥ 1.5 cm in the greatest dimension or definite extraprostatic extension/invasive behavior

PI-RADS Assessment of DWI

Signal intensity in a lesion should be visually compared to the average signal of "normal" prostate tissue in the histologic zone in which it is located.

Score	Peripheral Zone (PZ) or Transition Zone (TZ)
1	No abnormality (i.e., normal) on ADC and high b-value DWI
2	Linear/wedge shaped hypointense on ADC and/or linear/wedge shaped hyperintense on high b-value DWI
3	Focal (discrete and different from the background) hypointense on ADC and/or focal hyperintense on high b-value DWI; may be markedly hypointense on ADC or markedly hyperintense on high b-value DWI, but not both.
4	Focal markedly hypointense on ADC and markedly hyperintense on high b-value DWI;
5	Same as 4 but ≥ 1.5 cm in greatest dimension or definite extraprostatic extension/invasive behavior

PI-RADS Assessment of DCE

Score	Peripheral Zone (PZ) or Transition Zone (TZ)
(-)	no early or contemporaneous enhancement; or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W and/or DWI
(+)	focal, and; earlier than or contemporaneously with enhancement of adjacent normal prostatic tissues, and; corresponds to suspicious finding on T2W and/or DWI

PI-RADS Assessment for Overall Score

Peripheral Zone (PZ)

DWI	T2W	DCE	PI-RADS
1	Any*	Any	1
2	Any	Any	2
3	Any	-	3
		+	4
4	Any	Any	4
5	Any	Any	5

* "Any" indicates 1-5

Transition Zone (TZ)

T2W	DWI	DCE	PI-RADS
1	Any*	Any	1
2	≤3	Any	2
	≥4	Any	3
3	≤4	Any	3
	5	Any	4
4	Any	Any	4
5	Any	Any	5

* "Any" indicates 1-5

Assessment Without Adequate DWI

Peripheral Zone (PZ) and Transition Zone (TZ)

T ₂ W	DWI	DCE	PI-RADS
1	X	Any	1
2	X	Any	2
3	X	-	3
		+	4
4	X	Any	4
5	X	Any	5

Assessment Without Adequate DCE

Peripheral Zone (PZ): Determined by DWI Assessment Category

Transition Zone (TZ)

T ₂ W	DWI	DCE	PI-RADS
1	Any*	X	1
2	≤3	X	2
	≥4	X	3
3	≤4	X	3
	5	X	4
4	Any	X	4
5	Any	X	5

If both DWI and DCE are inadequate or absent, assessment should be limited to staging for determination of EPE.

Appendix G: Suggested Image Quality Evaluation Form for Institutional Audit of Prostate MRI

Adapted from PI-QUAL⁸⁸

1. T2-Weighted (T2W) MRI	
Obtained in axial plus coronal and/or sagittal planes	<input type="checkbox"/> YES <input type="checkbox"/> NO
Z axis correctly positioned to cover the entire prostate and seminal vesicles	<input type="checkbox"/> YES <input type="checkbox"/> NO
Score visualization of the following anatomy (1=Not visible/obscured, 2=Partially visible but indistinct or blurred, 3=Average, 4=Clearly visible, well defined and 5=Excellent visualization):	
Zonal Anatomy	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
“Capsule”	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
Seminal vesicles	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
Ejaculatory ducts	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
Sphincter muscles	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
Neurovascular bundles	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
Degree of motion artifact: 1=severe, 2=greater than average, 3=average, 4=less than average, minimal, 5=none	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
2. Diffusion-Weighted Imaging (DWI)	
Axial plane matches T2-W coverage	<input type="checkbox"/> YES <input type="checkbox"/> NO
Adequate coverage in Z direction (include seminal vesicles)	<input type="checkbox"/> YES <input type="checkbox"/> NO
High (≥ 1400 m ² /sec) b-value obtained (acquired or synthesized/calculated)	<input type="checkbox"/> YES <input type="checkbox"/> NO
Adequate ADC map	<input type="checkbox"/> YES <input type="checkbox"/> NO
Amount of rectal gas/distention	
Rectal volume: 1=Completely Collapsed, 2= minimal distension, 3 = average distension, 4=moderate distention, 5=Severely Distended	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5
Rectal content: 1=none, 2=mostly stool, 3=mostly liquid, 4=mostly gas.	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4
3. Dynamic Contrast Enhanced (DCE)-MRI	
Axial plane matches T2-W	<input type="checkbox"/> YES <input type="checkbox"/> NO
Adequate coverage in Z direction	<input type="checkbox"/> YES <input type="checkbox"/> NO
Pre-contrast T1 available	<input type="checkbox"/> YES <input type="checkbox"/> NO
Temporal resolution ≤ 15 seconds with at least 2 minutes of scan-time	<input type="checkbox"/> YES <input type="checkbox"/> NO
Fat suppression or subtraction provided	<input type="checkbox"/> YES <input type="checkbox"/> NO



Canadian Association of Radiologists
L'Association canadienne des radiologistes

CAR/CSAR Prostate MRI Survey Results

Survey Period: Dec 3, 2020 – Jan 10, 2021


Participation Rate: 46 responses

Average Time to complete: 15.5 mins


Purpose: Survey to collect data about the use of prostate MRI for the screening and diagnosis of prostate cancer and to provide the CAR and CSAR with direction for planning purposes. The survey was conducted in conjunction with the CSAR member survey, and respondents were informed that their feedback would inform a white paper on the use of prostate MRI.




Q10: Do you interpret, or are you planning to interpret prostate MRI?




Q11: How long (in years) have you been reading multi-parametric MRI?




Q12: If you do not currently interpret prostate MRI, when do you plan to train for this?




Q13: If you do interpret prostate MRI, how many do you interpret in one week, on average?




Q14: If you plan to learn how to read prostate MRI, what is your preference for the format of that training and learning?




Q15: If you need to brush up on the latest updates on how to read prostate MRI, what is your preference for the format of that training and learning?



Q16: Where do your referrals originate? (Check all that apply)



Q17: What proportion of your prostate MRI requests match or meet the following statements?




Q18: If you selected other in the prior question, please explain


- 1. Pain, hematospermia
- 2. Infertility
- 3. pelvic pain, hematospermia




Q19: On what magnet strength do you perform your prostate MRI?



Q20: If you use an endorectal coil, what material do you use to inflate the balloon?




Q21: Do you use contrast for your cases?




Q22: If you selected sometimes for the prior question, when do you use contrast?

- 1. Biochemical recurrence, PIRADS 3
- 2. Out of town patients, patients with pacemakers or hip prosthesis
- 3. When DWI likely to be degraded (eg THR), upgrading PZ P3 lesions in patients at intermediate risk, biochemical recurrence post RRP/XRT or focal Rx
- 4. To upgrade PR 3 peripheral zone observations
- 5. Post treatment, hip replacement, out of town
- 6. Out of town patients, hip replacements, post therapy
- 7. Out of town patients, hip prosthesis, pacemaker, post treatment

Q23: How do you obtain you high b-value: acquired, extrapolated, or both?



Q24: In what instances do you use extrapolated b-values?




"Only if there is some reason to perform DWI on the 1.5T scanner (eg. very bad artifact from arthroplasties). I try to avoid extrapolated b-values as much as possible."

"We obtain them, but they do not have enough diagnostic value"


"B1800 is always calculated from 1400"




Q25: What high b-value do you use?



Q26: How do you adjust window and level for interpreting the ADC map?



Q27: What set window and level do you use?




Q28, 29, 30: Do you use computer-aided diagnosis programs? If so, which vendor do you use and under which circumstances?


- **32** respondents answered No
- **1** respondent who answered **Yes** said that they use MIM for post gad analysis and for fusion biopsy planning




Q31: Do you have a waitlist?




Q32: How long is the waitlist?




Q33: Are the prostate MRIs you report used for fusion biopsies?




Q34: Does the radiologist or the urologist perform fusion biopsies in your institution?




Q35: If your institution performs fusion biopsies, which vendor is being used?









Q36: Do you have a dedicated director or radiologist lead for the Prostate MRI program +/- fusion?









Q37: How do you maintain quality and/or audit your reports?





Q 38: Do you, or does your institution?



Q 38: Do you, or does your institution?



Q 38: Do you, or does your institution?



Note: All survey respondents completing this section responded “No” to the question “Do you or does your institution perform spectroscopy”




Q39: Please elaborate on responses given in the prior question, especially in instances where you answered "sometimes."


- Have tried to train techs to recognize rectal gas and have patients evacuate with inconsistent results.
- If patients have a full rectum on scouts they are instructed to go to the bathroom before resuming the test. Extrapolated b-values only used if additional sequences are done on a 1.5T due to severe arthroplasty artifact. We use a low residue diet for a prep.
- Technologists will evacuate rectal air if there is a lot of air on the localizer sequence




Q40: Please rate how difficult it is to achieve the following:



Q41a: Please rate how difficult it is to achieve the following:



Q41b: Please rate how difficult it is to achieve the following:



Q42: Are there any challenges that you encounter that are not listed above?

Funding for a research assistant or assist to help collect cases for MDT. Getting funding and time for research

Limited MR resources

Too few radiologists have an active prostate imaging practice.

Follow up of biopsies from outside referring doctors

Support for MDT



Q43: What is/are the biggest challenges for you with regards to prostate MRI?

- Interobserver variability in interpretation, waitlist, time to develop or run the program
- Financial support to have the latest technology given the rapid evolution of the field
- Follow up/QA with urologists in order to improve diagnostic accuracy. Funding for fusion biopsy hardware.
- Dealing with artifact from rectal gas, optimizing quality on some magnets. Keeping up with demand from urologists.
- Volume, the number of demands, doing the fusion Bx by radiologist
- Relatively poor performance in the literature, including overlap of benign and malignant findings (esp central gland) and relatively low PPV compared to other "RADS". Limited pathologic correlation. Limited MR resources and resources required of the multiparametric Prostate MR protocol (including length of time, gadolinium, and antispasmodic agent).
- Hip prostheses. MR time
- Establishing an audit program. Capacity to perform an adequate volume of studies to maintain comfort level of reporting. Establishing an MR/US fusion biopsy program.



Q43 cont.

- Educating family physicians for referrals to private practice
- Access to magnet time, clinical history, and concerted audits.
- Patient prep
- Feedback from the urologist = none
- The main problems are that examinations performed in external institutions are often of poor technical quality and the radiologists who interpret them have little experience and are not very involved in prostate imaging. This is why our waiting list is very long because we receive many requests from peripheral centers to do these exams at our institution. I often received biopsy prescription of typical BPH nodule from outside institutions. Learning curve is steep and long but this is not well recognized.
- Transition zone analysis
- Optimizing technique, protocols and reporting across the province - no standardized processes. No standardized training requirements. Need Canada wide standards.
- Limited time on the 3T scanner results in long wait times

